NCT01926444View on ClinicalTrials.gov

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy

PHASE2CompletedINTERVENTIONAL
Enrollment

308

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
PainCancerColonic Diseases
Interventions
DRUG

GIC-1001

GIC-1001 oral tablet, white-coated, to be taken with water

Trial Locations (15)

10467

Montefiore Medical Center, The Bronx

20636

Mid-Atlantic Medical Research Centers, Hollywood

29118

Gastroenterology Associates of Orangeburg, Orangeburg

32720

Avail Clinical Research LLC, DeLand

33021

The Center for GI Disorders, Hollywood

55910

Mayo Clinic Rochester, Rochester

85259

Mayo Clinic, Scottsdale

91910

Precision Research Institute, Chula Vista

92114

Precision Research Institute, San Diego

92801

Anaheim Clinical Trials, Anaheim

08844

PharmaTrials, Hillsborough

V6Z 2K5

GIRI (GI Research Institute), Vancouver

L4L4Y7

Toronto Digestive Disease Associates, Toronto

H2X3H9

Clinique 1037, Montreal

H3Z 2P9

Spécialistes MD Specialists, Montreal

Sponsors
All Listed Sponsors
collaborator

JSS Medical Research Inc.

INDUSTRY

collaborator

Algorithme Pharma Inc

INDUSTRY

lead

gicare Pharma Inc.

INDUSTRY

NCT01926444 - A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy | Biotech Hunter | Biotech Hunter